JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patien

starstarstarstarstar

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

RSS Feed URL

Claim this podcast

Remove this podcast

Play Latest Episode:

Title: Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults

Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults

June 18th, 2020

Interview with Susan C. Gilchrist, MD, MS, author of Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults Go to Episode

Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases

June 4th, 2020

Interview with Chad G. Rusthoven, MD, author of Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases:… Go to Episode

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

April 16th, 2020

Interview with Charles Dolladille, MD, author of Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer Go to Episode

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC

April 9th, 2020

Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small… Go to Episode